No Clear Winner in BMS, Exelixis/Ipsen First-line Renal Cancer Race

 
• By Kevin Grogan

While the CheckMate-214 data on the Opdivo/Yervoy combo made the headlines at ESMO, a closer look at the results show there is plenty of room for Cabometyx to have sizeable market share.

Wrestlers
B-MS and Exelixis/Ipsen's renal cancer drugs are battling to be first-line therapy • Source: Shutterstock

More from Immuno-oncology

More from Anticancer